References
- 1. Tuttle KR, Bakris GL, Bilous RW, et al. (2014), Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes Care. 2014;37(10):2864–2883. doi:10.2337/dc14-129610.2337/dc14-1296417013125249672
- 2. Shahbazian H, Rezaii I. (2013). Diabetic kidney disease; review of the current knowledge. J Renal Inj Prev.;2(2):73–80. Published 2013 Jun 1. doi:10.12861/jrip.2013.24
- 3. Bailey RA, Wang Y, Zhu V, Rupnow MF. (2014), Chronic kidney disease in US adults with type 2 diabetes: An updated national estimate of prevalence based on Kidney Disease: Improving Global Outcomes (KDIGO) staging. BMC Res Notes 7: 415,10.1186/1756-0500-7-415409195124990184
- 4. Pugliese G, Penno G, Natali A, et.al (2019), New clinical and therapeutic issues. Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology on “The natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function”. Nutr Metab Cardiovasc Dis. Nov;29(11):1127-1150.
- 5. Ravid M, Brosh D, Ravid-Safran D et.al (1998). Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Arch Intern Med;158(9):998-1004.
- 6. e Boer IH, Rue TC, Cleary PA et.al (2011). Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort. Arch Intern Med.;171(5):412-20
- 7. Aziz KMA (2017). Association of high serum triglycerides and triglycerides/HDL ratio with raised HbA1c, creatinine, microalbuminuria and development of diabetic kidney disease and diabetic renal failure. Mathematical and statistical regression models of 10,370 diabetic patients. Clin Nephrol Res.;1(1):17-25.
- 8. Abrass CK (2004). Cellular lipid metabolism and the role of lipids in progressive renal disease. Am J Nephrol.;24(1):46-53.
- 9. Moorhead JF, Chan MK, El-Nahas M, Varghese Z (1982). Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet.;2(8311):1309-11.
- 10. Khavandi M, Duarte F, Ginsberg HN, Reyes-Soffer G (2017). Treatment of Dyslipidemias to Prevent Cardiovascular Disease in Patients with Type 2 Diabetes. Curr Cardiol Rep.;19(1):7. doi: 10.1007/s11886-017-0818-1. PMID: 28132397; PMCID: PMC5503120.10.1007/s11886-017-0818-1550312028132397
- 11. Marcovina S, Packard CJ (2006). Measurement and meaning of apolipoprotein AI and apolipoprotein B plasma levels. J Intern Med.;259(5):437-46. doi: 10.1111/j.1365-2796.2006.01648.x. PMID: 16629849.10.1111/j.1365-2796.2006.01648.x16629849
- 12. Okubo M, Hanada H, Matsui M, et.al (2014). Serum apolipoprotein B-48 concentration is associated with a reduced estimated glomerular filtration rate and increased proteinuria. J Atheroscler Thromb. 2014;21(9):974-82. doi: 10.5551/jat.23309. PMID: 2488262110.5551/jat.2330924882621
- 13. Ference BA, Kastelein JJP, Ray KK, et.al (2019). Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants With Risk of Coronary Heart Disease. JAMA.;321(4):364-373. doi: 10.1001/jama.2018.20045. PMID: 30694319; PMCID: PMC6439767.10.1001/jama.2018.20045643976730694319
- 14. Persson J, Nilsson J, Lindholm MW (2006). Cytokine response to lipoprotein lipid loading in human monocyte-derived macrophages. Lipids Health Dis.;5:17. doi: 10.1186/1476-511X-5-17. PMID: 16800873; PMCID: PMC1524960.10.1186/1476-511X-5-17152496016800873
- 15. Del Prato S, Felton AM, Munro N, Nesto R, Zimmet P, Zinman B (2005)., Global Partnership for Effective Diabetes Management. Improving glucose management: ten steps to get more patients with type 2 diabetes to glycaemic goal. Int J Clin Pract.;59(11):1345-55. doi: 10.1111/j.1742-1241.2005.00674.x. PMID: 16236091.10.1111/j.1742-1241.2005.00674.x16236091